Key result
Sertraline treatment resulted in modestly lower QIDS-C depression scores at 12 weeks compared with cognitive behavioral therapy.
Why the study?
Depression is common among patients receiving maintenance hemodialysis, but data on treatment acceptance and the comparative efficacy of therapies are limited.
Does cognitive behavioral therapy compared to sertraline improve depressive symptoms in patients receiving maintenance hemodialysis?
RCT (n=184)
open-label
parallel-group
Yes
Does cognitive behavioral therapy compared to sertraline improve depressive symptoms in patients receiving maintenance hemodialysis?
In patients on maintenance hemodialysis with depression, sertraline provided modestly better symptom improvement at 12 weeks compared to cognitive behavioral therapy, though with more adverse events.
Answers are grounded in this paper and cite their sources.
Sertraline modestly improves depressive symptoms over CBT in hemodialysis patients; extends RCT evidence on pharmacotherapy options in this population.
Background: Although depression is common among patients receiving maintenance hemodialysis, data on their acceptance of treatment and on the comparative efficacy of various therapies are limited. Objective: To determine the effect of an engagement interview on treatment acceptance (phase 1) and to compare the efficacy of cognitive behavioral therapy (CBT) versus sertraline (phase 2) for treating depression in patients receiving hemodialysis. Design: Multicenter, parallel-group, open-label, randomized controlled trial. (ClinicalTrials.gov: NCT02358343). Setting: 41 dialysis facilities in 3 U.S. metropolitan areas. Participants: Patients who had been receiving hemodialysis for at least 3 months and had a Beck Depression Inventory-II score of 15 or greater; 184 patients participated in phase 1, and 120 subsequently participated in phase 2. Intervention: Engagement interview versus control visit (phase 1) and 12 weeks of CBT delivered in the dialysis facility versus sertraline treatment (phase 2). Measurements: The primary outcome for phase 1 was the proportion of participants who started depression treatment within 28 days. For phase 2, the primary outcome was depressive symptoms measured by the Quick Inventory of Depressive Symptoms-Clinician-Rated (QIDS-C) at 12 weeks. Results: The proportion of participants who initiated treatment after the engagement or control visit did not differ (66% vs. 64%, respectively; P = 0.77; estimated risk difference, 2.1 [95% CI, -12.1 to 16.4]). Compared with CBT, sertraline treatment resulted in lower QIDS-C depression scores at 12 weeks (effect estimate, -1.84 [CI, -3.54 to -0.13]; P = 0.035). Adverse events were more frequent in the sertraline than the CBT group. Limitation: No randomized comparison was made with no treatment, and persistence of treatment effect was not assessed. Conclusion: An engagement interview with patients receiving maintenance hemodialysis had no effect on their acceptance of treatment for depression. After 12 weeks of treatment, depression scores were modestly better with sertraline treatment than with CBT. Primary Funding Source: Patient-Centered Outcomes Research Institute, Dialysis Clinic, Kidney Research Institute, and National Institute of Diabetes and Digestive and Kidney Diseases.
No takes yet. Share an insight, caveat, or question.
Mehrotra et al. (2019) conducted an RCT in Depression in patients receiving maintenance hemodialysis (n=184). Sertraline vs. Cognitive behavioral therapy (CBT) was evaluated on Depressive symptoms measured by the Quick Inventory of Depressive Symptoms-Clinician-Rated (QIDS-C) at 12 weeks (Effect estimate -1.84, 95% CI -3.54 to -0.13, p=0.035). Sertraline treatment resulted in modestly lower QIDS-C depression scores at 12 weeks compared with cognitive behavioral therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: